Pharmafile Logo

Pearl Therapeutics

- PMLiVE

AZ/Oxford University’s COVID-19 vaccine to be evaluated in children and young adults

First study to assess the safety and immune response of the vaccine in children

- PMLiVE

AZ forecasts growth in 2021 after revenues surge in Q4

Most recent quarter is first 'for many years' in which product sales were in excess of $7bn

- PMLiVE

WHO backs AZ/Oxford COVID-19 vaccine, including in older adults

WHO's Sage panel also recommends a two-dose regimen given eight to 12 weeks apart

- PMLiVE

AZ partners with IDT Biologika to bolster manufacturing for COVID-19 vaccine in EU

AZ is looking to accelerate vaccine output in Q2 2021

Covid-19: how is it affecting prescribing patterns?

Oli Hudson, Content Director at Wilmington Healthcare, analyses prescribing data in three key disease areas

Wilmington Healthcare

- PMLiVE

NIH trial of AZ’s long-acting COVID-19 antibody launches in the US

Study will evaluate efficacy of drug in patients hospitalised with COVID-19

- PMLiVE

South Africa puts AZ/Oxford COVID-19 vaccine roll-out on hold

Pre-print study results found jab offers 'minimal' protection against B.1.351 variant

- PMLiVE

UK launches world-first COVID-19 study evaluating a mixed-vaccine regimen

Participants could receive AZ/Oxford University's vaccine for their first dose and Pfizer/BioNTech's vaccine for their second

- PMLiVE

EU may restrict exports of some COVID-19 vaccines

Proposed strategy follows a confrontation between the EU and AstraZeneca

- PMLiVE

The UK reasserts that the AZ vaccine is ‘effective across all age groups’

Germany's draft guidance does not recommend the vaccine for people over 65

- PMLiVE

AZ and EU fail to solve COVID-19 vaccine delivery issues

AZ temporarily reduced Q1 deliveries to the EU last week

- PMLiVE

AZ refutes reports suggesting its COVID-19 vaccine is less effective in the elderly

German media reports suggested vaccine is less than 10% effective in the elderly

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links